Skip to main content
OpenTrials

Clinical trial condition

Hypergammaglobulinemia

Explore clinical trials studying Hypergammaglobulinemia. Study availability and eligibility vary by location and protocol.

137 public trials 35 recruiting studies
Refine in advanced search Browse all conditions

Hypergammaglobulinemia trial results

Active, not recruiting

Oxford Pre-cancerous Lymphoproliferative Disorders Study

NCT04023747

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations
  • Royal Bournemouth Hospital Bournemouth, United Kingdom
  • Russells Hall Hospital Dudley, United Kingdom
  • James Paget Hospital Great Yarmouth, United Kingdom
  • Leicester Royal Infirmary Leicester, United Kingdom
View all 17 locations
View Trial Details
Active, not recruiting

Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

NCT04144387

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Cliniques Universitaires Saint-Luc Brussels, Belgium
  • Institut Jules Bordet Brussels, Belgium
  • CHU UCL Namur ASBL Site Godinne Yvoir, Belgium
  • Centre Hospitalier Abbeville, France
View all 90 locations
View Trial Details
Active, not recruiting

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

NCT03289299

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
  • Indiana University Simon Cancer Center Indianapolis, Indiana, United States
  • University of Kansas Cancer Center Westwood, Kansas, United States
View Trial Details
Active, not recruiting

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

NCT02415413

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Hospital Clínic de Barcelona Barcelona, Spain
  • Hospital Universitari Germans Trias i Pujol Barcelona, Spain
  • Hospital Clínico San Carlos Madrid, Spain
  • Hospital Universitario 12 de Octubre Madrid, Spain
View all 16 locations
View Trial Details
Completed

A Real-world Study in Participants With Smoldering Multiple Myeloma

NCT06472778

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • CHRU de Tours - Hopital Trousseau Chambray-lès-Tours, France
  • CHU Montpellier Montpellier, France
  • Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source Orléans, France
  • Hopital Pitie Salpetriere Paris, France
View all 29 locations
View Trial Details
Completed

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

NCT03301220

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Arizona Oncology Associates, PC - HAL Phoenix, Arizona, United States
  • Innovative Clinical Research Inc Whittier, California, United States
  • Miami Cancer Institute Miami, Florida, United States
  • Emory University Atlanta, Georgia, United States
View all 163 locations
View Trial Details

Related conditions